On Tuesday, Shares of International Paper Co (NYSE:IP), gained 0.17% to $42.02. 2.62 million shares of the company were exchanged.
International Paper’s (IP) board of directors increased the company’s regular quarterly dividend by 10 percent from $0.40 to $0.44 per share for the period from October 1, 2015, to December 31, 2015, inclusive, on its common stock, par value $1.00. This increased regular dividend is payable on December 15, 2015, to shareholders of record at the close of business on November 16, 2015.
Additionally, the company also declared a regular quarterly dividend of $1.00 per share for the period from October 1, 2015, to December 31, 2015, inclusive, on the cumulative $4.00 preferred stock of the company. This dividend is also payable on December 15, 2015, to holders of record at the close of business on November 16, 2015.
International Paper Company operates as a paper and packaging company in North America, Europe, Latin America, Russia, Asia, Africa, and the Middle East. The company operates through three segments: Industrial Packaging, Printing Papers, and Consumer Packaging.
Shares of Ally Financial Inc (NYSE:ALLY), inclined 0.63% to $20.63, during its last trading session.
To recognize that it has surpassed 1 million retail deposit customers, Ally Bank, the direct banking partner of Ally Financial Inc. (ALLY), has named the second Monday in October of each calendar year National Online Bank Day. In addition, National Online Bank Day provides an opportunity to highlight the value, ease and convenience of banking with online-only institutions.
About 87 percent of U.S. households presently bank online, according to Javelin Strategy & Research¹. In the case of Ally Bank, its steady customer growth is the result of a highly competitive spectrum of products, features and services, combined with a growing population of technologically savvy consumers who like the ability to manage their online bank accounts whenever and wherever they want. The distinct cost advantage of Ally’s online model allows it to pass those savings along to its customers in the form of features they value most, such as competitive rates, minimal fees and a simpler, smarter way to bank.
Ally Bank customer-centric approach, counting 24/7 live customer service and convenient access via online banking and a broad variety of mobile apps, is another factor in its strong acceptance by consumers. The result is strong customer satisfaction and advocacy, in addition to industry recognition as a ‘Best Online Bank’ by a number of noteworthy personal finance outlets, counting Money Magazine®, Kiplinger’s Personal Finance, Go Banking Rates and My Bank Tracker.
Ally Financial Inc. provides financial products and services primarily to automotive dealers and their customers in the United States. It offers dealer financial services, counting a range of financial services and insurance products to automotive dealers and retail customers.
At the end of Tuesday’s trade, Shares of Novocure Ltd (NASDAQ:NVCR), inclined 6.65% to $27.60.
Novocure (NVCR) declared that the U.S. Food and Drug Administration (FDA) has approved Optune in combination with temozolomide for the treatment of adult patients with newly diagnosed glioblastoma (GBM). Optune is a portable, non-invasive device that delivers low-intensity, intermediate frequency, alternating electric fields – referred to as Tumor Treating Fields (TTFields) – that inhibit cancer cell replication and cause cancer cell death.
Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically noteworthy extension of overall survival in newly diagnosed GBM. The two-year survival rate among patients treated with Optune in combination with temozolomide was 50% higher than in patients treated with temozolomide alone. No noteworthy additive systemic toxicity was observed in the trial, and patients maintained stable quality-of-life, cognitive function and activities of daily living while using Optune.
The FDA approval follows a preceding review of the Optune Premarket Approval (PMA) supplement application. The FDA grants preceding review status to medical devices that are intended to treat life-threatening diseases and that offer clinically meaningful advantages over existing approved alternatives. Optune was formerly approved in April 2011 for the treatment of adult patients with GBM following tumor recurrence after receiving chemotherapy.
NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
